From Astra-Zeneca to Pfizer: When Protection of Originators’ Patents Ceases to be a “Right†and Becomes an Abuse of Dominance

Stefano Grassani

Antitrust Chronicle, 2012, vol. 7

Abstract: National agencies do not refrain from dealing with sensitive and critical mattersâ€â€such as the interplay between IP and antitrust lawâ€â€which one would assume the EU Commission would be primarily addressing. Stefano Grassani (Pavia e Ansaldo)

JEL-codes: G38 (search for similar items in EconPapers)
Date: 2012
References: Add references at CitEc
Citations Track citations by RSS feed

Downloads: (external link)
http://www.competitionpolicyinternational.com/from ... n-abuse-of-dominance (application/pdf)
Requires login and subscription

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: http://EconPapers.repec.org/RePEc:cpi:atchrn:7.2.2012:i=7747

Access Statistics for this article

More articles in Antitrust Chronicle from Competition Policy International
Series data maintained by Lindsay McSweeney ().